Published 2022
| Version v1
Publication
Effectiveness of Perampanel as the Only Add-on: Retrospective, Multicenter, Observational Real Life Study on epilepsy patients
- Creators
- Gasparini, Sara
- Ferlazzo, Edoardo
- Neri, Sabrina
- Cianci, Vittoria
- Iudice, Alfonso
- Bisulli, Francesca
- Bonanni, Paolo
- Caggia, Emanuele
- D'Aniello, Alfredo
- Di Bonaventura, Carlo
- DiFrancesco, Jacopo C
- Domina, Elisabetta
- Dono, Fedele
- Gambardella, Antonio
- Marini, Carla
- Marrelli, Alfonso
- Matricardi, Sara
- Morano, Alessandra
- Paladin, Francesco
- Renna, Rosaria
- Striano, Pasquale
- Pascarella, Angelo
- Ascoli, Michele
- Aguglia, Umberto
- Others:
- Gasparini, Sara
- Ferlazzo, Edoardo
- Neri, Sabrina
- Cianci, Vittoria
- Iudice, Alfonso
- Bisulli, Francesca
- Bonanni, Paolo
- Caggia, Emanuele
- D'Aniello, Alfredo
- Di Bonaventura, Carlo
- Difrancesco, Jacopo C
- Domina, Elisabetta
- Dono, Fedele
- Gambardella, Antonio
- Marini, Carla
- Marrelli, Alfonso
- Matricardi, Sara
- Morano, Alessandra
- Paladin, Francesco
- Renna, Rosaria
- Striano, Pasquale
- Pascarella, Angelo
- Ascoli, Michele
- Aguglia, Umberto
Description
Perampanel (PER) is indicated as adjunctive antiseizure medication (ASM) in adolescents and adults with epilepsy. Data from clinical trials show good efficacy and tolerability, while limited information is available on the routine clinical use of PER, especially when used as only add-on treatment.
Additional details
- URL
- http://hdl.handle.net/11567/1096179
- URN
- urn:oai:iris.unige.it:11567/1096179
- Origin repository
- UNIGE